Salarius Pharma up after FDA lifts hold on cancer study

Decoy Therapeutics

09/05/2023 14:01

** Salarius Pharmaceuticals Inc's shares  SLRX.O  up 10.2%
at $2.37 premarket
    ** Drug developer says the U.S. Food and Drug Administration
(FDA) has removed partial clinical hold on co's early to mid
stage study of its experimental drug to treat cancer that forms
in bones and soft tissue 
    ** SLRX said the decision comes after FDA reviewed
comprehensive safety data submitted by the co
    ** SLRX's CEO says the move puts the company back on track
to engage with the FDA on topics relating to further clinical
development of the drug
    ** As of last close, stock had risen ~41% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))